Series A · 2026-11-05 · Healthcare
Alethio Therapeutics raises $86.9M
71
AI Score
Amount
$86.9M
Round
Series A
Lead
Sofinnova Partners, RA Capital
HQ
Abingdon-on-Thames, GB
Why it matters: The round's syndicate and the ATX-011 timeline show how a University of Oxford spin-out is moving a targeted MPN antibody toward Phase 1/2a.
Alethio Therapeutics, an Abingdon-on-Thames biopharma spun out of the University of Oxford in 2021.
- Participants:
- Oxford Science Enterprises, Cancer Research Horizons, University of Oxford
- Source:
- EU-Startups ↗ · Midu summary
Deal Dossier PRO
Pro feature
Deal Dossier for Alethio Therapeutics
Company, lead and participating investors, founders, and verified public contact channels — sourced, generated on demand.
Generate dossier — ProFigures marked company-reported are unaudited. Not investment advice. Request a correction or removal (team@midu.si).
More deals with Sofinnova Partners
Recent Healthcare rounds
Subscribe to the newsletters
Free, by email. No account needed. Pick one or both.
No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.
Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing